Life at the periphery

Rubrik: Originale

(Treffer aus pharmind, Nr. 09, Seite 1241 (2021))

Klingler F | Mathias S | Otte K

Life at the periphery / How cell surface proteins can influence bioprocesses · Klingler F¹, Mathias S^1,2, Otte K¹ · ¹Institute of Applied Biotechnology, University of Applied Sciences Biberach, Biberach und Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach
Biopharmaceuticals Cell aggregation Cell surface proteins Chinese hamster ovary cells Surfaceome Cell surface proteome Chinese hamster ovary (CHO) cells are currently the main production hosts for biopharmaceuticals. Over the past decades, commercial bioprocesses have been steadily optimized to create optimal environments for the cultured cells to grow in suspension, stay viable and produce desired products at high titres and quality. However, the suspension-adapted CHO cells were originally derived from a spontaneously immortalized putative epithelial cell and sometimes regress into patterns forming large cell aggregates. This cell adhesion and aggregation may result in loss of cell viability and/or a decrease in ...

Unravelling of molecular bottlenecks in pharmaceutical production cell lines

Rubrik: Biotechnologie

(Treffer aus pharmind, Nr. 12, Seite 1604 (2020))

Mathias S | Otte K

Unravelling of molecular bottlenecks in pharmaceutical production cell lines / Mathias and Otte • Molecular bottlenecks · Mathias S¹, Otte K² · ¹Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach und Hochschule Biberach, Fakultät Biotechnologie, Biberach
Therapeutic proteins represent a class of macromolecules capable of addressing a variety of yet unmet medicinal needs. In contrast to small molecule drugs, these complex biological therapeutics require to be produced by cell-based sources. This need for biological production systems results in long-lasting development timelines making the manufacture of biopharmaceuticals highly expensive. Among the different classes of recombinant therapeutic proteins, mAbs and antibody-derived formats have grown to become the dominant product class within the biopharmaceutical market [ 1 ]. However, the increasing number of non-naturally existing antibody-derived molecules such as multi-specific antibody formats often cause low production efficiencies. This may ...